Serina Therapeutics Files 8-K
Ticker: SER · Form: 8-K · Filed: Jul 29, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, exhibits
TL;DR
Serina Therapeutics filed an 8-K, mostly standard exhibits. Check the filings for any surprises.
AI Summary
Serina Therapeutics, Inc. (formerly AgeX Therapeutics, Inc.) filed an 8-K on July 29, 2024, reporting on financial statements and exhibits. The company, incorporated in Delaware and headquartered in Huntsville, Alabama, operates in the Pharmaceutical Preparations sector. This filing does not appear to contain specific financial transaction details or material events beyond the standard reporting of exhibits.
Why It Matters
This filing indicates Serina Therapeutics is meeting its regulatory reporting obligations. Investors should review the exhibits for any newly disclosed material information.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any immediate negative events or significant financial changes.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- AgeX Therapeutics, Inc. (company) — Former company name
- July 29, 2024 (date) — Date of report
- Huntsville, Alabama (location) — Company headquarters
FAQ
What is the primary purpose of this 8-K filing for Serina Therapeutics?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as required by the SEC.
When was this 8-K filing submitted?
This 8-K filing was submitted on July 29, 2024.
What was Serina Therapeutics' former company name?
Serina Therapeutics, Inc.'s former company name was AgeX Therapeutics, Inc.
In which state was Serina Therapeutics, Inc. incorporated?
Serina Therapeutics, Inc. was incorporated in Delaware.
What is the business address of Serina Therapeutics, Inc.?
The business address of Serina Therapeutics, Inc. is 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-07-29 08:30:54
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SER NYSE American Indic
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 22KB
- ex99-2.htm (EX-99.2) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 444KB
- ex99-1_002.jpg (GRAPHIC) — 342KB
- ex99-1_003.jpg (GRAPHIC) — 1332KB
- ex99-1_004.jpg (GRAPHIC) — 600KB
- ex99-1_005.jpg (GRAPHIC) — 476KB
- ex99-1_006.jpg (GRAPHIC) — 420KB
- ex99-1_007.jpg (GRAPHIC) — 701KB
- ex99-1_008.jpg (GRAPHIC) — 710KB
- ex99-1_009.jpg (GRAPHIC) — 577KB
- ex99-1_010.jpg (GRAPHIC) — 570KB
- ex99-1_011.jpg (GRAPHIC) — 799KB
- ex99-1_012.jpg (GRAPHIC) — 678KB
- ex99-1_013.jpg (GRAPHIC) — 609KB
- ex99-1_014.jpg (GRAPHIC) — 449KB
- ex99-1_015.jpg (GRAPHIC) — 755KB
- ex99-1_016.jpg (GRAPHIC) — 635KB
- ex99-1_017.jpg (GRAPHIC) — 669KB
- ex99-1_018.jpg (GRAPHIC) — 732KB
- ex99-1_019.jpg (GRAPHIC) — 524KB
- ex99-1_020.jpg (GRAPHIC) — 850KB
- ex99-1_021.jpg (GRAPHIC) — 549KB
- ex99-1_022.jpg (GRAPHIC) — 418KB
- ex99-1_023.jpg (GRAPHIC) — 854KB
- ex99-1_024.jpg (GRAPHIC) — 554KB
- ex99-1_025.jpg (GRAPHIC) — 509KB
- ex99-1_026.jpg (GRAPHIC) — 430KB
- ex99-1_027.jpg (GRAPHIC) — 564KB
- ex99-1_028.jpg (GRAPHIC) — 634KB
- ex99-1_029.jpg (GRAPHIC) — 553KB
- ex99-1_030.jpg (GRAPHIC) — 485KB
- ex99-1_031.jpg (GRAPHIC) — 485KB
- ex99-1_032.jpg (GRAPHIC) — 613KB
- ex99-1_033.jpg (GRAPHIC) — 225KB
- ex99-1_034.jpg (GRAPHIC) — 510KB
- ex99-2_001.jpg (GRAPHIC) — 19KB
- 0001493152-24-029379.txt ( ) — 28163KB
- ser-20240729.xsd (EX-101.SCH) — 3KB
- ser-20240729_lab.xml (EX-101.LAB) — 33KB
- ser-20240729_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: July 29, 2024 By: /s/ Steven Ledger Interim Chief Executive Officer